Open AccessCancer Treatment-induced Changes in Renal Function in Patients with Tumors – Update on Current Knowledge
Author(s) -
Tomáš Pokrivčák,
Alexandr Poprach
Publication year - 2018
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.14735/amko201828
Subject(s) - medicine , nephrotoxicity , immunotherapy , renal function , intensive care medicine , clinical trial , malignancy , kidney , cancer , disease , kidney disease , drug , oncology , urinary system , tumor lysis syndrome , chemotherapy , kidney cancer , pharmacology
Renal abnormalities associated with malignancy are common with renal impairment occurring in about 60% of patients with tumors. Kidney disease may occur as a result of direct or indirect effects of tumors on kidneys and the urinary tract. Systematic oncology treatment can affect renal function in two ways, via direct toxic effects on kidney structure and indirectly via dehydration or tumor lysis syndrome. Since 2004, the Food and Drug Administration has approved a number of potentially nephrotoxic chemotherapeutics, targeted drugs, and immunotherapeutics for the treatment of solid tumors.